NURIX THERAPEUTICS IN

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

06 أكتوبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 أكتوبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

14 سبتمبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 أغسطس 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

03 أغسطس 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces $40 Million Registered Direct Offering

08 يوليو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces $55 Million Registered Direct Offering

07 يوليو 2022 16:03:06 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

07 يوليو 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

30 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

10 يونيو 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

03 يونيو 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

26 مايو 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

17 مايو 2022 06:00:02 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

11 مايو 2022 15:02:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Host R&D Day on May 26, 2022

09 مايو 2022 15:02:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

08 أبريل 2022 12:02:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

07 أبريل 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

05 أبريل 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

04 أبريل 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

29 مارس 2022 15:01:00 بحسب Nasdaq GlobeNewswire